Author:
Pickin Mark,Cooper Cindy L,Chater Timothy,O'Hagan Anthony,Abrams Keith R,Cooper Nicola J,Boggild Mike,Palace Jackie,Ebers George,Chilcott James B,Tappenden Paul,Nicholl Jon
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,General Medicine
Reference13 articles.
1. NICE: Technology Appraisal Guidance No.32. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. 2002, London
2. Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH, on behalf of the Cost Effectiveness of Multiple Sclerosis Therapies Study Group: Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ. 2003, 326 (7388): 522-10.1136/bmj.326.7388.522.
3. Department of Health: Cost Effective Provision of Disease Modifying Therapies for people with Multiple Sclerosis. Health Service Circular. 2002
4. Association of British Neurologists: Guidelines for Use of Beta Interferons and Glatiramer Acetate in Multiple Sclerosis. 2001
5. Kurtzke JF: Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983, 33: 1444-1452.
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献